aztreonam has been researched along with cefiderocol in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 5 (83.33) | 2.80 |
| Authors | Studies |
|---|---|
| Bethel, CR; Bonomo, RA; Cmolik, A; Domitrovic, TN; Goldberg, JA; Hoyer, D; Hujer, AM; Hujer, KM; Jacobs, MR; Kreiswirth, BM; Kumar, V; Logan, LK; Marshall, EK; Marshall, SH; Nguyen, H; O'Shea, M; Papp-Wallace, KM; Perez, F; Plummer, MS; Rudin, SD; Spencer, EJ; van den Akker, F; van Duin, D | 1 |
| Hsu, AJ; Tamma, PD | 1 |
| Bianco, G; Boattini, M; Casale, R; Cavallo, R; Comini, S; Costa, C; Iannaccone, M | 1 |
| Nordmann, P; Ortiz de la Rosa, JM; Poirel, L; Sadek, M | 1 |
| Akova, M; Aslan, AT; Harris, P; Isler, B; Paterson, DL | 1 |
| Le Terrier, C; Nordmann, P; Poirel, L | 1 |
2 review(s) available for aztreonam and cefiderocol
| Article | Year |
|---|---|
Defining the Role of Novel β-Lactam Agents That Target Carbapenem-Resistant Gram-Negative Organisms.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; Boronic Acids; Carbapenems; Cefiderocol; Ceftazidime; Cephalosporins; Cilastatin, Imipenem Drug Combination; Drug Combinations; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Heterocyclic Compounds, 1-Ring; Meropenem; Tazobactam | 2019 |
Treatment strategies for OXA-48-like and NDM producing
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; Bacterial Proteins; beta-Lactamases; Carbapenem-Resistant Enterobacteriaceae; Cefiderocol; Colistin; Drug Combinations; Humans; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests | 2022 |
4 other study(ies) available for aztreonam and cefiderocol
| Article | Year |
|---|---|
A γ-Lactam Siderophore Antibiotic Effective against Multidrug-Resistant Gram-Negative Bacilli.
Topics: Animals; Anti-Bacterial Agents; Bacterial Proteins; Binding Sites; Catalytic Domain; Crystallography, X-Ray; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Half-Life; Lactams; Mice; Microbial Sensitivity Tests; Molecular Docking Simulation; Penicillin-Binding Proteins; Pseudomonas aeruginosa; Siderophores | 2020 |
Occurrence of multi-carbapenemases producers among carbapenemase-producing Enterobacterales and in vitro activity of combinations including cefiderocol, ceftazidime-avibactam, meropenem-vaborbactam, and aztreonam in the COVID-19 era.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; Bacterial Proteins; beta-Lactamases; Boronic Acids; Cefiderocol; Ceftazidime; Cephalosporins; COVID-19; Drug Combinations; Humans; Meropenem; Microbial Sensitivity Tests | 2022 |
Impact of Acquired Broad-Spectrum β-Lactamases on Susceptibility to Cefiderocol and Newly Developed β-Lactam/β-Lactamase Inhibitor Combinations in Escherichia coli and Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; beta-Lactamase Inhibitors; beta-Lactamases; Cefiderocol; Ceftazidime; Cephalosporins; Drug Combinations; Escherichia coli; Escherichia coli Infections; Humans; Lactams; Microbial Sensitivity Tests; Pseudomonas aeruginosa | 2022 |
In vitro activity of aztreonam in combination with newly developed β-lactamase inhibitors against MDR Enterobacterales and Pseudomonas aeruginosa producing metallo-β-lactamases.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; beta-Lactamase Inhibitors; beta-Lactamases; Cefiderocol; Microbial Sensitivity Tests; Pseudomonas; Pseudomonas aeruginosa | 2022 |